Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23 , Pages S15-S22 , December 2009

3 Rationale for treatment and therapeutic options in Cushing's disease

  • Paul M. Stewart

      Affiliations

    • Centre for Endocrinology, Diabetes and Metabolism, Clinical & Experimental Medicine, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • Corresponding Author InformationPaul M. Stewart, FRCP, FMedSci. Centre for Endocrinology, Diabetes and Metabolism, Clinical & Experimental Medicine, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Tel.: +44 1214158708; fax: +44 1214158811
    • ,
  • Stephan Petersenn

      Affiliations

    • Department of Endocrinology and Division of Laboratory Research, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
    • Corresponding Author InformationCorresponding author. Stephan Petersenn, MD. Tel.: +49 201 7232854; fax: +49 201 7235976

References 

  1. Biller BMK , Grossman AB , Stewart PM , et al.   Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement . Journal of Clinical Endocrinology and Metabolism . 2008;93:2454–2462
  2. Arnaldi G , Angeli A , Atkinson AB , et al.   Diagnosis and complications of Cushing's syndrome: a consensus statement . Journal of Clinical Endocrinology and Metabolism . 2003;88:5593–5602
  3. Plotz CM , Knowlton AI , Ragan C . The natural history of Cushing's syndrome . American Journal of Medicine . 1952;13:597–614
  4. Ross EJ , Lynch DC . Cushing's syndrome – killing disease: discriminatory value of signs and symptoms aiding early diagnosis . Lancet . 1982;320(8299):646–649
  5. Cushing H . The basophil adenomas of the pituitary and their clinical manifestations . Bull Johns Hopkins Hospital . 1932;50:137–195
  6. Lindholm J , Juul S , Jørgensen JOL , et al.   Incidence and late prognosis of Cushing's syndrome: a population-based study . Journal of Clinical Endocrinology and Metabolism . 2001;86:117–123
  7. Swearingen B , Biller BMK , Barker FG , et al.   Long-Term Mortality after Transsphenoidal Surgery for Cushing Disease . Annals of Internal Medicine . 1999;130:821–824
  8. Davies JH , Storr HL , Davies K , et al.   Final adult height and body mass index after cure of paediatric Cushing's disease . Clinical Endocrinology . 2005;62:466–472
  9. Hermus AR , Smals AG , Swinkels LM , et al.   Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome . Journal of Clinical Endocrinology and Metabolism . 1995;80:2859–2865
  10. Lindsay JR , Nansel T , Baid S , et al.   Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission . Journal of Clinical Endocrinology and Metabolism . 2006;91:447–453
  11. Magiakou MA , Mastorakos G , Zachman K , Chrousos GP . Blood pressure in children and adolescents with Cushing's syndrome before and after surgical cure . Journal of Clinical Endocrinology and Metabolism . 1997;82:1734–1738
  12. Arnaldi G , Mancini T , Polenta B , Boscaro M . Cardiovascular risk in Cushing's syndrome . Pituitary . 2004;7(4):253–256
  13. Faggiano A , Pivonello R , Spiezia S , et al.   Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission . Journal of Clinical Endocrinology and Metabolism . 2003;88:2527–2533
  14. Magiakou MA , Mastorakos G , Chrousos GP . Final stature in patients with endogenous Cushing's syndrome . Journal of Clinical Endocrinology and Metabolism . 1994;79:1082–1085
  15. Blevins LS , Christy JH , Khajavi M , Tindall GT . Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas . Journal of Clinical Endocrinology and Metabolism . 1998;83:63–67
  16. Bochicchio D , Losa M , Buchfelder M . Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group . Journal of Clinical Endocrinology and Metabolism . 1995;80:3114–3120
  17. Hughes NR , Lissett CA , Shalet SM . Growth hormone status following treatment for Cushing's syndrome . Clinical Endocrinology (Oxford) . 1999;51:61–66
  18. Trainer PJ , Lawrie HS , Verhelst J , et al.   Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment . Clinical Endocrinology (Oxford) . 1993;38:73–78
  19. Morris D , Grossman A . Cushing's syndrome – The diagnosis and differential diagnosis . In:  Gaillard RC editors. The ACTH Axis Pathogenesis, Diagnosis and Treatment . Kluwer Academic Publishers; 2003;p. 229–257
  20. Sonino N , Zielezny M , Fava GA , et al.   Risk factors and long-term outcome in pituitary-dependent Cushing's disease . Journal of Clinical Endocrinology and Metabolism . 1996;81:2647–2652
  21. Kemink L , Pieters G , Hermus A , et al.   Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease . Journal of Clinical Endocrinology and Metabolism . 1994;79:887–889
  22. Devin JK , Allen GS , Cmelak AJ , et al.   The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease . Stereotactic and Functional Neurosurgery . 2004;82:254–262
  23. Schulte HM , Benker G , Reinwein D , et al.   Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects . Journal of Clinical Endocrinology and Metabolism . 1990;70:1426–1430
  24. Miller JW , Crapo L . The medical treatment of Cushing's syndrome . Endocrine Reviews . 1993;14:443–458
  25. Riedl M , Maier C , Zettinig G , et al.   Long term control of hypercortisolism with fluconazole: case report and in vitro studies . European Journal of Endocrinology . 2006;154:519–524
  26. Verhelst JA , Trainer PJ , Howlett TA , et al.   Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome . Clinical Endocrinology . 1991;35:169–178
  27. Gormley MJ , Hadden DR , Kennedy TL , et al.   Cushing's syndrome in pregnancy – treatment with metyrapone . Clinical Endocrinology . 1982;16:283–293
  28. Heaney HP , Fernando M , Yong WH , Melmed S . Functional PPAR-γ receptor is a novel therapeutic target for ACTH secreting pituitary adenomas . Nature Medicine . 2002;8:1281–1287
  29. Ambrosi B , Dall'Asta C , Cannavo S , et al.   Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease . European Journal of Endocrinology . 2004;151:173–178
  30. Giraldi F , Scaroni C , Arvat E , et al.   Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease . Clinical Endocrinology . 2006;64:219–224
  31. Suri D , Weiss RE . Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease . Journal of Clinical Endocrinology and Metabolism . 2005;90:1340–1346
  32. Pivonello R , Ferone D , de Herder WW , et al.   Dopamine receptor expression and function in corticotroph pituitary tumors . Journal of Clinical Endocrinology and Metabolism . 2004;89:2452–2462
  33. Hale AC , Coates PJ , Doniach I , et al.   A bromocriptine-responsive corticotroph adenoma secreting α-MSH in a patient with Cushing's disease . Clinical Endocrinology . 1988;28:215–223
  34. Koppeschaar HPF , Croughs RJM , Thijssen JHH , Schwarz F . Response to neurotransmitter modulating drugs in patients with Cushing's disease . Clinical Endocrinology . 1986;25:661–667
  35. Pivonello R , De Martino MC , Cappabianca P , et al.   The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery . Journal of Clinical Endocrinology and Metabolism . 2009;94:223–230
  36. Webster J , Piscitelli G , Polli A , et al.   A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea: Cabergoline Comparative Study Group . The New England Journal of Medicine . 1994;331(14):904–909
  37. Schade R , Andersohn F , Suissa S , et al.   Dopamine agonists and the risk of cardiac-valve regurgitation . The New England Journal of Medicine . 2007;356(1):29–38
  38. Zanettini R , Antonini A , Gatto G , et al.   Valvular heart disease and the use of dopamine agonists for Parkinson's disease . The New England Journal of Medicine . 2007;356(1):39–46
  39. Batista DL , Zhang X , Gejman R , et al.   The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas . Journal of Clinical Endocrinology and Metabolism . 2006;91:4482–4488
  40. Hofland LJ . Somatostatin and somatostatin receptors in Cushing's disease . Molecular and Cellular Endocrinology . 2008;286:199–205
  41. Hofland LJ , Van Der Hoek J , Feelders R , et al.   The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 3 . European Journal of Endocrinology . 2005;152:645–654
  42. Boscaro M , Ludlam WH , Atkinson B , et al.   Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial . Journal of Clinical Endocrinology and Metabolism . 2009;94:115–122
  43. Johanssen S , Allolio B . Mifepristone (RU 486) in Cushing's syndrome . European Journal of Endocrinology . 2007;157:561–569

PII: S1521-690X(09)70004-1

doi: 10.1016/S1521-690X(09)70004-1

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23 , Pages S15-S22 , December 2009

Article Tools

* Image Usage & Resolution